4:08 PM ET
8-K
Investor Presentation
Prime Medicine Investor Presentation
Prime Medicine filed an updated corporate presentation and provided preliminary financial estimates for the quarter ended September 30, 2026. The company estimated its cash, cash equivalents, and short-term investments at approximately $61.2 million, excluding restricted cash. The presentation outlines the company's strategic pipeline, including upcoming clinical data readouts for PM577a and PM647 expected in 2027.